Home / Guides / Unapproved GLP-1s: FDA status
Compounded, counterfeit and “research” GLP-1s: what the FDA says
Contents
Prepared by: Research Desk. Sources are linked for verification.
Demand for GLP-1-based weight-loss medicines has created a parallel market. It runs from state-licensed compounding pharmacies to anonymous websites selling vials labelled “for research use only”. In law, these are very different categories. This page sets out each one using the FDA’s own published position. It is checked against the agency’s pages as of the date at the bottom.
The three categories at a glance
Category
FDA review of safety, effectiveness and quality?
Examples
FDA-approved drug
Yes, before marketing
Branded semaglutide, tirzepatide and orforglipron products, each for its labelled uses
Compounded drug
No [1]
Pharmacy-made versions prepared for an individual prescription
Unapproved, “research use” or counterfeit
No
Retatrutide or cagrilintide sold online; fake branded pens
1. FDA-approved GLP-1 drugs
These have been through the full new-drug review: clinical trials, manufacturing inspections and labelling review. As of a May 2026 industry pipeline summary, two oral GLP-1 drugs were approved for weight management. One is a higher-dose oral semaglutide and the other is orforglipron, marketed by Eli Lilly as Foundayo. A high-dose injectable semaglutide had also been approved [2]. Each product is approved only for the uses on its label.
2. Compounded GLP-1 drugs
Compounding is when a licensed pharmacist or outsourcing facility prepares a medication, typically for a specific individual. The FDA states plainly that compounded drugs “are not FDA approved”. That means the agency “does not review compounded drugs for safety, effectiveness or quality before they are marketed” [1].
FDA’s stated position [1]:
Compounded drugs should be used only where an FDA-approved drug cannot meet an individual’s medical needs.
FDA’s guidance refers to dispensing by prescription through a state-licensed pharmacy.
The agency has also described specific quality concerns with compounded GLP-1s [1]:
Multi-dose vials. FDA notes that contamination risk rises after a vial is first opened, and its guidance sets a 28-day discard limit regardless of the compounder’s label.
Shipping temperature. FDA has received complaints of injectable GLP-1s arriving warm or with inadequate ice packs. It flags warm arrival as a quality concern.
The rules on which GLP-1 ingredients may be compounded have been shifting as drug shortages ended and FDA reviewed bulk-substance nominations. We track these changes on our news page with dated sources.
3. Unapproved and “research use only” GLP-1s
FDA’s statement here is explicit [1]:
“Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.”
FDA also says it has warned [1]:
telehealth companies for marketing unapproved drugs such as retatrutide, including direct marketing to consumers;
active-ingredient distributors for selling retatrutide and other GLP-1 drugs to compounders;
outsourcing facilities for repackaging retatrutide.
In other words, retatrutide sold to the public in the U.S. today, however it is labelled, is outside the legal supply chain. The same applies to standalone cagrilintide. Both remain investigational: they are being tested in clinical trials, not approved. Our pipeline guide covers what those trials have shown so far.
FDA’s telehealth red flags
The agency lists warning signs that a company may be selling unsafe or unapproved products [1]. FDA’s list describes a company that:
claims a compounded drug is “the same as” an FDA-approved drug;
offers deep discounts or prices that seem too good to be true;
sends medicine that looks different from earlier shipments, or arrives damaged or without instructions;
doesn’t require a screening and a prescription from a licensed prescriber;
has no licensed health professional available for follow-up questions;
has spelling errors or incorrect pharmacy addresses on the label.
Outside the United States
Other regulators have their own rules, and generic semaglutide has begun to appear in some countries as patents expire. We’re building a dated, sourced country tracker. Until it’s published, we don’t make country-specific legal claims on this page.
Reporting problems
FDA collects adverse-event and product-quality reports on GLP-1 products through its MedWatch program [3].
Status checked: 18 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.